To assess the efficacy and adverse effects of Oxcarbazepine and Brivaracetam in children with self limited focal epilepsies by intervention for a duration of 6 months.
Phase 2
- Conditions
- Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset
- Registration Number
- CTRI/2024/04/065485
- Lead Sponsor
- AIIMS Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
children between 2 years and 18 years of age with SeLFEs
caregiver giving consent for participation
caregiver willing for follow up
Exclusion Criteria
Children with Epilepsies other than SeLFEs
caregiver not giving consent
children with known allergies to Oxcarbazepine or Brivaracetam
past history of renal impairment, SJS, psychosis or suicidal ideation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.The efficacy of Oxcarbazepine and Brivaracetam in the reduction of seizure frequency in children with SeLFEsTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1.Adverse effects of Oxcarbazepine and Brivaracetam during the study period <br/ ><br>2.cognitive performance of children with SeLFEs after treatment with Oxcarbazepine and Brivaracetam. <br/ ><br>Timepoint: 6 months